

Supplementary Material

Browning Effects of a Chronic Pterostilbene Supplementation in Mice Fed a High-Fat Diet

Martina La Spina ^{1,†,‡}, Eva Galletta ^{1,2,†}, Michele Azzolini ^{1,§}, Saioa Gomez Zorita ^{3,4}, Sofia Parrasia ¹, Marika Salvalaio ⁵, Andrea Salmaso ^{1,6} and Lucia Biasutto ^{1,6,*}

¹ Department of Biomedical Sciences, University of Padova, 35131 Padova, Italy

² Department of Biology, University of Padova, 35131 Padova, Italy

³ Nutrition and Obesity Group, Department of Pharmacy and Food Science, University of the Basque Country (UPV/EHU) and Lucio Lascaray Research Institute, 01006 Vitoria, Spain

⁴ CIBEROBN Physiopathology of Obesity and Nutrition, Institute of Health Carlos III, 01006 Vitoria, Spain

⁵ Department of Pharmaceutical and Pharmacological Sciences, University of Padova, 35131 Padova, Italy

⁶ Padova Unit, CNR Neuroscience Institute, 35131 Padova, Italy

* Correspondence: lucia.biasutto@cnr.it

† These authors contributed equally to this work

‡ Current address: Cell Biology and Physiology Center, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA.

§ Current address: Department of Physiology and Pharmacology, Karolinska Institutet, 17177 Stockholm, Sweden




Figure S1. Insulin tolerance tests in (a), (c) male and (b), (d) female mice. Measurements were performed after (a), (b) 18 weeks or (c), (d) 28 weeks from the beginning of the high-fat diet regimen. N $\geq$ 7 for each condition; mean values $\pm$ SEM.

Table S1. Tissue levels of Pt, Pt-sulfate (PtS) and Pt-glucuronide (PtGluc) after chronic administration of Pt at three different dosages. N = 4, mean values $\pm$ SEM.

Tissue	Dosage (μ mol/kg/day)	Pt (nmol/g)	PtS (nmol/g)	PtGluc (nmol/g)
SM	88	0.68 $\pm$ 0.14	0	0
	176	0.59 $\pm$ 0.05	0.34 $\pm$ 0.34	0.77 $\pm$ 0.77
	352	1.03 $\pm$ 0.17	0.47 $\pm$ 0.36	1.71 $\pm$ 0.54
Bl	88	0.11 $\pm$ 0.06	0.25 $\pm$ 0.09	0.25 $\pm$ 0.08
	176	0	0.36 $\pm$ 0.07	0.51 $\pm$ 0.19
	352	0	0.57 $\pm$ 0.09	1.06 $\pm$ 0.25
L	88	0.48 $\pm$ 0.08	1.81 $\pm$ 0.32	4.31 $\pm$ 0.79
	176	0.77 $\pm$ 0.12	2.82 $\pm$ 0.59	9.58 $\pm$ 2.48
	352	1.15 $\pm$ 0.22	4.87 $\pm$ 1.71	17.47 $\pm$ 11.81
Br	88	0.37 $\pm$ 0.37	0	0
	176	0	0	0
	352	0.56 $\pm$ 0.38	0	0
K	88	0.51 $\pm$ 0.30	1.73 $\pm$ 0.55	1.46 $\pm$ 0.33
	176	0.05 $\pm$ 0.05	1.87 $\pm$ 0.17	1.72 $\pm$ 0.21
	352	0.83 $\pm$ 0.28	2.67 $\pm$ 0.71	3.58 $\pm$ 0.75
At-ing	88	1.76 $\pm$ 0.96	0.43 $\pm$ 0.05	0.53 $\pm$ 0.20
	176	1.08 $\pm$ 0.25	0.56 $\pm$ 0.21	0.75 $\pm$ 0.29
	352	5.29 $\pm$ 2.98	0.50 $\pm$ 0.08	1.21 $\pm$ 0.25
At-epid	88	2.18 $\pm$ 1.21	0	0.14 $\pm$ 0.14
	176	5.62 $\pm$ 3.44	0	0
	352	6.61 $\pm$ 4.04	0	0

¹ SM = skeletal muscle; Bl = blood; L = liver; Br = brain; K = kidney; AT-ing = inguinal adipose tissue; AT-epid = epididymal adipose tissue.

Table S2. List and sequences of the primers used for rtPCR analysis.

Gene	Primer
<i>Cidea</i>	F: GCCGTGTTAAGGAATCTGCTG R: TGCTCTTCTGTATCGCCCAGT
<i>Cited1</i>	F: ATTTATCGGACTTCTGCCCAG R: TTGCGATCCTTCACTCCAAG
<i>Ebf2</i>	F: GGGATTCAAGATACGCTAGGAAG R: GGAGGTTGCTTTTCAAATGGG
<i>Fgf21</i>	F: CAAATCCTGGGTGTCAAAGC R: CATGGGCTTCAGACTGGTAC
<i>Gapdh</i>	F: TGTGTCCGTCGTGGATCTGA R: TTGCTGTTGAAGTCGCAGGAG
<i>Pat2</i>	F: AGCCACCCCTCTCAATCT R: TGCCTTTGACCAGATGAACC
<i>Pgc1α</i>	F: AAGAGCGCCGTGTGATTTAC R: TCCATTCTCAAGAGCAGCGA
<i>Pparaα</i>	F: CCTGAACATCGAGTGTGCGAA R: ACGGCAGTACTGGCATTGT
<i>Pparγ</i>	F: GGAAGACCACTCGCATTCCTT R: TCGCACTTTGGTATTCTTGGAG
<i>Prdm16</i>	F: CAGCACGGTGAAGCCATTC R: GCGTGCATCCGCTTGTG
<i>Sirt1</i>	F: GCTGACGACTTCGACGACG R: TCGGTCAACAGGAGGTTGTCT
<i>Tbx1</i>	F: GGCAGGCAGACGAATGTTC R: TTGTCATCTACGGGCACAAAG
<i>Ucp1</i>	F: GGCATTTCAGAGGCAAATCAGCT R: CAATGAACACTGCCACACCTC